News

In Gene Therapy, viral vector stability and integrity must be carefully investigated before scaling up production. Specific process steps can be evaluated to understand what impact they have on viral particle integrity. Viral particle...

An example of how Hitachi High Technologies and Vironova AB walk the talk in TEM research and business collaboration.   To achieve great advancement by relying and leveraging on each others core competencies and competitive edge, with sustainable,...

We did it! Today Team Vironova won the People's Choice Finals in Hitachi´s Transformation Awards in Las Vegas.

Accurate and reliable analytics are crucial in the development and manufacturing of viral-based drugs. In this webcast key concepts and strategies will be discussed how to apply analytical information to the development of these emerging therapies.

Characterization and analysis of subvisible particles of biological origin can be challenging or give insufficient information. In this study Adeno associated virus (AAV) particles contaminated by host cell proteasomes are analysed with direct...

The Annual General Meeting of Vironova AB will be held on Monday 24 June 2019 at 15.00, at the Company's premises, at Gävleatan 22, in Stockholm - Sweden.

May 15-17, London, UK, EU

We are in the finals of the Third China Innovation & Entrepreneurship International Competition in Shenzhen.   Vironova won the "Swedish Overseas Division Competition" on March 26th in the "Third China Innovation & Entrepreneurship International...

Vironova are attending the conference in Boston to follow key industry trends, and join the conversation in the field of gene therapy. March 26-28, Boston, Massachusetts, USA

Meet Vironova at Bioprocessing Summit Europe 2019 Bioprocessing , March 19-21, Lisbon, Portugal. Vironova's Marketing Director Nina Forsberg will host and moderate a Round table, 19th of March at 16:45 on the topics and needs for analytical methods...